By Order of the Federal Maritime Commission. Joseph C. Polking, Secretary. [FR Doc. 96–1781 Filed 1–30–96; 8:45 am] BILLING CODE 6730–01–M

#### FEDERAL RESERVE SYSTEM

### Community First Financial Group, Inc.; Notice of Proposal to Engage de novo in Permissible Nonbanking Activities

The company listed in this notice has given notice under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage de novo, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether commencement of the activity can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 14, 1996

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. Community First Financial Group, Inc., English, Indiana; to acquire a 9 percent equity interest in Independent Bankers Life Insurance Company of Indiana, Phoenix, Arizona (Company), a reinsurance company wholly owned by bank holding companies, and thereby to engage *de novo* in underwriting credit life, accident, and health insurance directly related to extensions of credit by the respective subsidiary banks of Company's shareholders, pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y. These activities would be conducted in the State of Indiana.

Board of Governors of the Federal Reserve System, January 25, 1996. Jennifer J. Johnson, Deputy Secretary of the Board. [FR Doc. 96–1813 Filed 1–30–96; 8:45 am]

## F & M National Corporation, et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than February 26, 1996.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. F & M National Corporation, Winchester, Virginia; to merge with FB&T Financial Corporation, Fairfax, Virginia, and thereby indirectly acquire Fairfax Bank & Trust Company, Fairfax, Virginia.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230

South LaSalle Street, Chicago, Illinois 60690:

1. First Michigan Bank Corporation, Holland, Michigan; to acquire 100 percent of the voting shares of Arcadia Financial Corporation, Portage, Michigan, and thereby indirectly acquire Arcadia Bank & Trust Company, Kalamazoo, Michigan.

C. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201– 2272

1. East Texas National, Inc., Palestine, Texas, and East Texas-Dover, Inc., Wilmington, Delaware; to acquire 100 percent of the voting shares of American Bank, Huntsville, Texas.

Board of Governors of the Federal Reserve System, January 25, 1996. Jennifer J. Johnson, Deputy Secretary of the Board. [FR Doc. 96–1814 Filed 1–30–96; 8:45 am] BILLING CODE 6210–01–F

# GENERAL SERVICES ADMINISTRATION

### Performance Review Boards for Small Client Agencies Serviced by the General Services Administration; Names of Members

Correction

Under the Federal Retirement Thrift Board on page 56059 in the issue of Monday, November 6, 1995 make the following correction. Name correction to Veda R. Charrow from Vera D. Charrow, Director of Communications.

Dated: January 23, 1996.
Calvin R. Snowden,
Director, Agency Liaison Division.
[FR Doc. 96–1798 Filed 1–30–96; 8:45 am]
BILLING CODE 6820–34–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

#### **NIOSH Meetings**

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meetings.

Name: Setting a National Occupational Research Agenda: Regional Meetings. Date: February 21, 1996.

*Time:* 1–5 p.m.

Place: The State of Illinois Building Assembly Hall, 100 West Randolph, Chicago, IL 60601. Date: February 23, 1996.

Time: 1-5 p.m.

Place: Thomas P. O'Neill Federal Building, Auditorium, 10 Causeway, Boston, MA 02222

Date: February 27, 1996.

Time: 6-9 p.m.

Place: Museum of History and Industry Auditorium, 2700 24th Avenue East, Seattle, WA 98112.

*STATUS:* Open to the public, limited only by the space available.

Purpose: NIOSH will sponsor three public meetings of worker safety and health stakeholders to develop a national agenda for occupational safety and health research for the next decade. The goals of the public meetings are.

- To receive comments regarding occupational safety and health from stakeholders and the public;
- To increase NIOSH's understanding of occupational safety and health issues and to learn about occupational safety and health concerns in the community; and
- To set research priorities for the national occupational research agenda.

These regional meetings are intended to promote participation by workers, organized labor, businesses, local chamber of commerce, health professionals, researchers, State and local government officials, elected officials, and the public to develop the national agenda. The meetings enable NIOSH officials to learn about worker safety and health concerns from stakeholders and the public.

The tentative agenda of the meetings includes a summary by the Director of NIOSH of the work in developing a national research agenda for occupational safety and health research followed by five minute presentations by participants. Participants may present their perspectives on critical worker safety and health and research priorities. Research priorities for consideration include health effects, hazardous exposures, work environments, industries, occupations, and populations associated with significant occupational disease, injury, disability, fatalities, and topics of growing importance.

Matters To Be Discussed: As the lead federal health agency for research into the causes and prevention of work injuries and diseases, NIOSH is responsible to assess the state of knowledge and define research needs and priorities. The national research agenda will assist NIOSH and the occupational safety and health research community to establish priorities and target scientific needs for the next decade that offer the greatest potential for advancing the safety and health of workers. Establishing these priorities is especially important due to increasing fiscal constraints on occupational safety and health research in the public and private sectors. The agenda will be used by decision-makers and scientists working and employed in government, corporate, labor, university, and private research programs to plan and implement occupational health research and prevention activities.

Prior to holding public meetings, together with external experts, NIOSH developed a discussion list of approximately 50 research

priorities for the national occupational research agenda. The discussion list was expanded based on written comments and oral presentations given at a public meeting on November 30, 1995, and at a working group meeting of researchers held on December 12, 1995. The expanded list of research priorities are:

#### Health Response

- Traumatic Injury
  - —Amputation Injuries
  - —Eye Injury
  - —Electrocutions
  - —Falls
  - —Inhalation Injury
- Musculoskeletal disorders of the neck, shoulder & other upper extremities
- Musculoskeletal disorders of the lower back
- Fertility and pregnancy outcomes
- Occupational Asthma
- Pneumoconioses
- Hypersensitivity Lung Disease
- Occupational Chronic Diseases (Selected)
  - —Chronic Obstructive Lung Disease
  - -Chronic Renal Disease
  - –Ischemic Heart Disease
  - Neurodegenerative Disease (Congnitive & Movement Disorders)
- —Anxiety and Depression
- Psychological disorders other than Anxiety and Depression
- Occupational Infectious Diseases
- Immune Dysfunction
- Neuroimmune Function
- Hearing Loss due to noise and nonauditory exposures
- Occupational Dermatitis
- Premature Disability
- Latex allergy

#### Exposure

- Chemical Mixtures (Including Hazardous Waste)
- Pesticides
- Solvents
- Oils their Substitutes and Related derivatives (e.g., Cutting Fluids, Diesel)
- Indoor Environment
- · Thermal stresses
- Mineral and Synthetic Fibers
- Silica
- Metals and Related Compounds
- Hormonally Active Substances
- Violence/Assaults
- Motor Vehicles
- Heavy Machinery (including Farm equipment)
- Hand Tools
- Biomechanical Stressors (including manual material handling)
- Noise
- Electric and Magnetic Fields
- Behavioral Risk Factors
- Falling objects
- Lead
- Pharmaceuticals (manufacture and administration)
- Robots
- Interactions

Work Environment, Workforce, Work Sector

- Work Organization
  - -Extended work shift
- —Shift work
- · Changing Economy and Workforce

- · Emerging Technologies and Problems
- Vulnerable Populations
- —Aging workforce
- —Child labor (including adolescents)
- -Home work
- -Migrant workers
- Temporary/contingent workforceMinorities
- Psychosocial factors
- Costs of occupational disease and injury (economic and social)
- Social inequality & health
- Environmental justice
- Occupational health/occupational disease & injury costs and benefits of prevention
  - Construction
- Agriculture
- Small Businesses
- Service workers
- Health Care
- Mining
- Transportation
- Hotel/restaurant workers

### Research Process

- Intervention Research
- Effectiveness Research (e.g. training)
- Economic Analysis: Cost benefit and workers' compensation
- International Occupational Health Research
- Clinical Methods Research
  - Develop methods for occupational disease and practice guidelines
- Engineering and Technological Solutions
- Exposure Assessment Methods Development
- Hazard Surveillance
- Disease Surveillance
- Injury Surveillance
- Risk Assessment Methods Development
- Identification of Molecular Correlates of Cancer and other Chronic Diseases
- Health Services Research (in a changing health care & workplace environment)
- Respirator research & other personal protective equipment research
- Information dissemination & Health communication
- · Community & region-based studies
- Strategies for worker/employer empowerment
- Barriers to implementation of prevention efforts
- Sector focussed research

From this list and additional items that are recommended, NIOSH will produce a final agenda of 15–25 scientific priorities for advancing safety and health.

NIOSH is seeking public comment until March 6, 1996, to assure that the final agenda includes input from the broadest base of occupational safety and health expertise. In addition to the three Regional meetings described in this announcement, the process for receipt of public comment includes the following elements: (1) Corporate and worker liaison committees and a stakeholder's outreach committee will assist NIOSH to obtain input from employers, employees, health officials, health professionals, scientists, and public health, advocacy, scientific, industry and labor organizations; (2) A public meeting was held on November 30, 1995, to obtain input on the research priorities, criteria for selection of priorities,

and the process for developing the agenda; (3) Three working groups including researchers, health professionals, and representatives of stakeholder organizations will meet before the Regional meetings are convened to provide individual input and recommendations based on the communities they represent; (4) A final public meeting will be held on March 1, 1996, in Washington, DC, to present a preliminary research agenda and receive public comment. The public is encouraged to provide oral comments at the public meetings and written comments as soon as possible. Written comments may be submitted until the close of business, March 6, 1996.

The final agenda will be presented at a scientific symposium commemorating the 25th anniversary of the Occupational Safety and Health Act on April 29, 1996.

NIOSH encourages the public to provide recommendations on research priorities, criteria for determining priorities, and the process of developing the research agenda. To receive more information, contact Ms. Kathy Sykes through the NIOSH toll-free information service. On-site registration will be available; however, to assist in planing for the meeting, advance registration is requested. To register in advance to attend and to speak at the Regional meetings, please contact Ms. Diane Manning. If registering in writing, please provide your name, address, phone and fax number, and indicate if you wish to make a presentation.

Addresses: Written public comments on the National Occupational Research Agenda should be mailed to Ms. Diane Manning, NIOSH, CDC, Robert A. Taft Laboratories, M/S C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513/533–8450, FAX 513/533–8285.

Contact Person for Additional Information: Ms. Kathy Sykes, NIOSH, CDC, 200 Independence Avenue, Room 317B, Washington, DC 20201, telephone NIOSH toll-free number 800/356–4674, or 202/401–3747, FAX 202/260–1898.

Dated: January 24, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–1828 Filed 1–30–96; 8:45 am] BILLING CODE 4163–19–M

#### Food and Drug Administration

## Advisory Committees; Notice of Meetings

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in

open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

**MEETINGS:** The following advisory committee meetings are announced:

Medical Imaging Drugs Advisory Committee

Date, time, and place. February 15, 1996, 8:30 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; Leander B. Madoo, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Medical Imaging Drugs Advisory Committee, code 12540.

General function of the committee. The committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 9, 1996, and submit a brief statement of the general nature of the evidence or the arguments they wish to present, the names and addresses of proposed participants, and an indication of the

approximate time required to make their comments.

Open committee discussion. The committee will discuss and begin drafting "Points to Consider (PTC) for Developing Medical Imaging Agents.' The purpose of the meeting is to provide the committee opportunity to work together on this draft and not primarily to hear presentations. The agents encompassed will include radiologic contrast media and nuclear medicine pharmaceuticals. Written comments will be accepted until April 15, 1996, and will be available in the Dockets Management Branch for public inspection under docket number 95N-0414 (Dockets Management Branch, HFA-305, Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857).

Medical Imaging Drugs Advisory Committee

Date, time, and place. February 16, 1996, 8:30 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 3 p.m.; Leander B. Madoo, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4695, or William Freas, Center for Biologics Evaluation and Research (HFM-21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Medical Imaging Drugs Advisory Committee, code 12540.

General function of the committee. The committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 9, 1996, and submit a brief statement of the general nature of the evidence or the arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.